Surgeon and thoracic surgical oncologist Bryan Burt was named chief of thoracic surgery and professor of surgery at UCLA Health and the David Geffen School of Medicine at UCLA.Â
Sora Ely joined the George Washington University Cancer Center and the GW Medical Faculty Associates as a thoracic surgeon. She treats benign and malignant pathologies of the chest and foregut. Her clinical interests include lung cancer screening, treatment of lung and esophageal cancer, treatment of mediastinal masses, including thymoma, and benign foregut surgery.Â
Kornelia Polyak and Alana L. Welm will receive awards at the 2023 San Antonio Breast Cancer Symposium for their significant contributions to breast cancer research.
Ethan Basch, a UNC Lineberger Comprehensive Cancer Center researcher, received $3 million in research funding from the Patient-Centered Outcomes Research Institute, or PCORI, to support a multi-institutional initiative to implement electronic patient-reported outcomes, or ePRO, in oncology practices across the country.
Andrew Frankart received a five-year, $729,000 American Cancer Society/American Society for Radiation Oncology Clinician Scientist Development Grant to lead a clinical trial at the University of Cincinnati Cancer Center that will test the safety and effectiveness of a more targeted radiation dose for patients with large tumors.
University of New Mexico Comprehensive Cancer Center has opened a clinic to offer screening, minimally invasive testing, and follow-up for lung cancer as part of the institution’s lung cancer screening program.
Cancer Research UK set out how the next U.K. Government could reduce cancer mortality rates by preventing thousands of future cancers as well as dramatically improving cancer survival.
The Translational Genomics Research Institute, part of City of Hope, established a fellowship in glioblastoma multiforme research. The Lori Lane/Andrew Spyrow Fellowship honors the lives of Lori Lane and Andrew Spyrow who fought GBM bravely, teaching all of us to experience the joy of life and dedicating their journey to the advancement of treatment improving the quality and longevity of life for those facing this devastating cancer.
FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies.
A planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma produced positive headline results.Â
